Core Viewpoint - Kenvue, a global consumer goods giant known for brands like Johnson's Baby and Tylenol, announced a 3.5% global workforce reduction to facilitate its acquisition by Kimberly-Clark, amid declining performance and ongoing controversies surrounding its products [1][2][4]. Group 1: Financial Performance - Kenvue's net sales for 2025 decreased by 2.1% to $15.124 billion, while net profit increased by 42.7% to $1.470 billion. However, adjusted net profit fell by 5.6% to $2.076 billion, and adjusted gross margin declined by 0.2% to 60.2% [1][6]. - Organic sales for Kenvue dropped by 2.2% in 2025, with organic volume down by 2.3%, while pricing and mix contributed a 0.1% increase [1][6]. - Kenvue's three main business segments all experienced declines in net sales, with personal care down 2.3% to $6.4 billion, skin health and beauty down 3.0% to $4.1 billion, and essential health down 1.2% to $4.6 billion [6]. Group 2: Workforce Reduction and Corporate Strategy - Kenvue's board approved a plan to optimize its operational model, resulting in a net reduction of approximately 3.5% of its global workforce, with expected costs of $250 million by 2026, primarily related to IT and employee expenses [2][3]. - The company aims to enhance performance and streamline operations under the new management team, which aligns with previously stated operational priorities [3][4]. Group 3: Acquisition by Kimberly-Clark - Kimberly-Clark announced plans to acquire Kenvue for $48.7 billion, with both companies' shareholders overwhelmingly approving the acquisition proposals [4][6]. - The merger is expected to create a combined entity with sales surpassing Unilever's beauty and personal care segment, second only to Procter & Gamble's health division [6]. - Both Kenvue and Kimberly-Clark have faced sluggish growth, with Kimberly-Clark's net sales declining from $20.4 billion in 2023 to $16.4 billion in 2025, and a net profit drop of 20.6% to $2.021 billion in 2025 [7][8].